Martingale Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Martingale Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.25M	Buy	167,893 +27,929	+20%	+$614K	0.1%	209
2026 Q1	$3.12M	Buy	139,964 +30,645	+28%	+$732K	0.08%	250
2025 Q4	$2.92M	Buy	109,319 +8,991	+9%	+$215K	0.07%	241
2025 Q3	$2.14M	Buy	100,328 +31,048	+45%	+$734K	0.05%	298
2025 Q2	$1.49M	Buy	+69,280	New	+$1.29M	0.04%	373
2023 Q3	–	Sell	-10,368	Closed	-$248K	–	777
2023 Q2	$248K	Sell	10,368 -4	-0%	-$89	﹤0.01%	730
2023 Q1	$195K	Sell	10,372 -2	-0%	-$38	﹤0.01%	783
2022 Q4	$165K	Buy	+10,374	New	+$162K	﹤0.01%	802
2016 Q4	–	Sell	-6,900	Closed	-$220K	–	955
2016 Q3	$220K	Sell	6,900 -10,644	-61%	-$361K	﹤0.01%	916
2016 Q2	$570K	Sell	17,544 -808	-4%	-$27K	0.01%	647
2016 Q1	$514K	Buy	+18,352	New	+$400K	0.01%	646
2013 Q4	–	Sell	-7,500	Closed	-$207K	–	980
2013 Q3	$207K	Buy	+7,500	New	+$157K	0.01%	951

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Martingale Asset Management's ACAD Position: Q2 2026 in Review

Martingale Asset Management increased its Acadia Pharmaceuticals (ACAD) stake by 20% in Q2 2026, buying an estimated $614K and bringing the position to 167,893 shares worth $4.25M. The position accounts for 0.1% of the portfolio, ranked #209.

Martingale Asset Management first reported a position in ACAD in Q3 2013 and has held it in 12 quarters since. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Martingale Asset Management held 167,893 shares of Acadia Pharmaceuticals worth $4.25M as of Q2 2026.
Martingale Asset Management bought 27,929 Acadia Pharmaceuticals shares in Q2 2026, an estimated $614K.
Acadia Pharmaceuticals made up 0.1% of Martingale Asset Management's portfolio in Q2 2026, its #209 holding.
Martingale Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2013 and has held it in 12 quarters since.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.